Moynahan, Mary Ellen
Chen, David
He, Wei
Sung, Patricia
Samoila, Aliaksandra
You, Daoqi
Bhatt, Trusha
Patel, Parul
Ringeisen, Francois
Hortobagyi, Gabriel N
Baselga, Jose
Chandarlapaty, Sarat
Article History
Received: 15 July 2016
Revised: 21 December 2016
Accepted: 11 January 2017
First Online: 9 February 2017
Competing interests
: MEM: Grant and personal fees from Novartis; patent related to biomarkers for response to PI3K inhibitors pending. GNH: personal fees from Merck, Eli Lilly, Peregrine Pharmaceuticals, Novartis, and Celgene as consultant; personal fees from Novartis, Bayer, Metastat, Pfizer, Antigen Express, and Galena Biopharma as scientific/advisory committee member. SC: Grant from Novartis and Eli Lilly; personal fees from Foresite Capital, Chugai Pharmaceuticals, Oncotheryeon, and Astra Zeneca. DC, WH, PP, and FR are Novartis employees. The remaining authors declare no conflict of interest.